Trial Profile
A Phase I Pharmacokinetic and Safety Study of Sorafenib + Capecitabine in Advanced Solid Tumors.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Nov 2013
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Sorafenib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 03 May 2011 Planned End Date changed from 1 Jan 2010 to 1 Dec 2011 as reported by ClinicalTrials.gov.
- 01 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 May 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.